Papadimitropoulos Emmanuel, Wells George, Shea Beverley, Gillespie William, Weaver Bruce, Zytaruk Nicole, Cranney Ann, Adachi Jonathan, Tugwell Peter, Josse Robert, Greenwood Carol, Guyatt Gordon
Endocr Rev. 2002 Aug;23(4):560-9. doi: 10.1210/er.2001-8002.
To review the effect of vitamin D on bone density and fractures in postmenopausal women.
We searched MEDLINE and EMBASE from 1966 to 1999 and examined citations of relevant articles and proceedings of international meetings. We contacted osteoporosis investigators and primary authors to identify additional studies and to obtain unpublished data.
We included 25 trials that randomized women to standard or hydroxylated vitamin D with or without calcium supplementation or a control and measured bone density or fracture incidence for at least 1 yr.
For each trial, three independent reviewers assessed the methodological quality and abstracted data.
Vitamin D reduced the incidence of vertebral fractures [relative risk (RR) 0.63, 95% confidence interval (CI) 0.45-0.88, P < 0.01) and showed a trend toward reduced incidence of nonvertebral fractures (RR 0.77, 95% CI 0.57-1.04, P = 0.09). Most patients in the trials that evaluated vertebral fractures received hydroxylated vitamin D, and most patients in the trials that evaluated nonvertebral fractures received standard vitamin D. Hydroxylated vitamin D had a consistently larger impact on bone density than did standard vitamin D. For instance, total body differences in percentage change between hydroxylated vitamin D and control were 2.06 (0.72, 3.40) and 0.40 (-0.25, 1.06) for standard vitamin D. At the lumbar spine and forearm sites, hydroxylated vitamin D doses above 50 microg yield larger effects than lower doses. Vitamin D resulted in an increased risk of discontinuing medication in comparison to control as a result of either symptomatic adverse effects or abnormal laboratory results (RR 1.37, 95% CI 1.01-1.88), an effect that was similar in trials of standard and hydroxylated vitamin D.
Vitamin D decreases vertebral fractures and may decrease nonvertebral fractures. The available data are uninformative regarding the relative effects of standard and hydroxylated vitamin D.
综述维生素D对绝经后女性骨密度和骨折的影响。
我们检索了1966年至1999年的MEDLINE和EMBASE数据库,并查阅了相关文章的引用文献以及国际会议的论文集。我们联系了骨质疏松症研究人员和主要作者,以确定其他研究并获取未发表的数据。
我们纳入了25项试验,这些试验将女性随机分为接受标准维生素D或羟基化维生素D(加或不加钙补充剂)或对照组,并测量骨密度或骨折发生率至少1年。
对于每项试验,三名独立的评审员评估方法学质量并提取数据。
维生素D降低了椎体骨折的发生率[相对危险度(RR)0.63,95%置信区间(CI)0.45 - 0.88,P < 0.01],并且显示出非椎体骨折发生率降低的趋势(RR 0.77,95%CI 0.57 - 1.04,P = 0.09)。评估椎体骨折的试验中的大多数患者接受了羟基化维生素D,而评估非椎体骨折的试验中的大多数患者接受了标准维生素D。羟基化维生素D对骨密度的影响始终大于标准维生素D。例如,羟基化维生素D与对照组之间全身百分比变化的差异为2.06(0.72,3.40),标准维生素D为0.40(-0.25,1.06)。在腰椎和前臂部位,羟基化维生素D剂量高于50微克时比低剂量产生更大的效果。与对照组相比,由于有症状的不良反应或实验室结果异常,维生素D导致停药风险增加(RR 1.37,95%CI 1.01 - 1.88),这一效应在标准维生素D和羟基化维生素D的试验中相似。
维生素D可降低椎体骨折发生率,并可能降低非椎体骨折发生率。关于标准维生素D和羟基化维生素D的相对效果,现有数据未提供足够信息。